News
Cmed Celebrates One Year Anniversary of encapsia®
Cmed announced its one-year anniversary of the launch of encapsia®, an innovative cloud-based clinical data suite of Apps that helps biotech and pharma sponsors transform the way data is captured, monitored and reviewed in clinical trials. ...
News
KP415 Phatmacokinetic Single And Multiple Dose Trial Preliminary Results Announced By KemPharm
KemPharm, Inc. , a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced preliminary results of KP415.109. A Phase I trial designed to assess the relative pharmacokinetics (PK) of three different...
News
J & J Announces Partnership with CSIR-IMTECH to Develop Innovative New Tuberculosis Treatments
Johnson & JohnsonPrivate Limited today announced a new partnership with the Institute of Microbial Technology (IMTECH), part of the Council of Scientific and Industrial Research (CSIR), to unlock the potential of Indian science and help accelerate the discovery of...
News
selvita and the leukemia & lymphoma society announce partnership to advance sel120 into phase i for aml patients
Selvita S.A. and The Leukemia & Lymphoma Society (LLS) announced a partnership to co-fund further preclinical and clinical development of a targeted therapy to treat patients with acute myeloid leukemia (AML). Selvita has discovered and is...
News
FDA Issues Emergency Use Authorization for Thermo Fisher Scientific’s Zika Virus Assay
Thermo Fisher Scientific, the world leader in serving science announced that the U.S. FDA has issued an Emergency Use Authorization for the company's new TaqPath Zika Virus Kit. The TaqPath Zika Virus Kit is authorized only...
News
Aridis Is Enrolling Patients in Pivotal Trial of Its Antibiotic-resistant Pneumonia Therapy Aerucin
Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel anti-infectives and immunotherapies for infectious diseases, announced that it is now actively enrolling patients in a global pivotal study of Aerucin®, the Company’s broadly reactive monoclonal antibody...
News
KALYDECO® ( ivacaftor ) Approved By FDA For More Than 600 People Ages 2 And Older With Cystic Fibrosis Who Have Certain Residual Function...
Vertex Pharmaceuticals Incorporated announced that the U.S. FDA has approved KALYDECO® (ivacaftor) for use in more than 600 people with CF ages 2 and older who have one of five residual function mutations that result in a splicing defect...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
















